- Ventripoint Diagnostics (TSXV:VPT), an artificial intelligence healthcare stock focused on heart analysis technology, has received the European Union’s CE certification for its latest offering, VMS+ 4.0
- The solution offers affordable results equivalent to magnetic resonance imaging
- Ventripoint is an industry leader in applying AI technology to echocardiography
- Ventripoint Diagnostics stock has given back 11.11 per cent year-over-year, but has gained 33.33 per cent since 2019
Ventripoint Diagnostics (TSXV:VPT), an artificial intelligence healthcare stock focused on heart analysis technology, has received the European Union’s CE certification for its latest offering, VMS+ 4.0.
VMS+ 4.0 is designed to deliver a significant improvement in user experience through automated image processing, leading to streamlined workflow and a reduction in operator time without compromising accuracy.
The solution is based on Ventripoint’s proprietary Knowledge Based Reconstruction technology, which provides cost-effective volumetric cardiac measurements equivalent to magnetic resonance imaging (MRI).
The certification allows Ventripoint to continue commercialization efforts for VMS+ 4.0 in the E.U. and other countries that recognize the CE certification.
VMS+ 4.0 holds a medical device license in Canada and is under review by the U.S. Food and Drug Administration.
Ventripoint’s flagship VMS+ 3.2 is used by leading hospitals in the United States, European Union, Canada and the United Kingdom.
Leadership insights
“We are delighted to achieve CE mark certification and will introduce the enhanced capabilities of the new version to European cardiologists and healthcare providers,” Hugh MacNaught, Ventripoint’s president and chief executive officer, said in a statement. “This is a key step in our commercialization plan as we continue to advance our technology leadership and impact by advancing the state-of-the-art in echocardiography. The advances introduced in VMS+ 4.0 provide clinicians with the potential to image a broader range of patients, which expands our market opportunity. The engineering breakthroughs in this latest version of VMS+ provide healthcare providers with a powerful tool that delivers accurate and reliable cardiac output measurements in a more efficient manner, and without the restrictions associated with MRI.”
About Ventripoint Diagnostics
Ventripoint is an industry leader in applying AI technology to echocardiography.
Ventripoint Diagnostics stock (TSXV:VPT) is up by 6.67 per cent, trading at C$0.16 per share as of 9:45 am ET. The stock has given back 11.11 per cent year-over-year, but has gained 33.33 per cent since 2019.
Join the discussion: Find out what everybody’s saying about this AI healthcare stock on the Ventripoint Diagnostics Ltd. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Ventripoint Diagnostics)
